IQVIA combines a dominant global CRO franchise, irreplaceable healthcare data, AI-enabled efficiency gains, and strong cash generation into a discounted compounder with asymmetric five-year upside.
Overview
IQVIA is a global life-sciences intelligence and clinical research leader formed from IMS Health and Quintiles. Its hybrid model combines CRO services with proprietary healthcare data, analytics, SaaS, and commercial solutions, allowing it to support drug sponsors from trial design through commercialization. R&DS contributes roughly 55%–60% of revenue, while Commercial Solutions contributes 40%–45%. The company’s key advantage is its unmatched global patient-data asset and integrated clinical-commercial platform, creating strong switching costs and differentiated execution capabilities.